Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Accumulated Expenses: 2013-2025

Historic Accumulated Expenses for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $10.3 million.

  • Theravance Biopharma's Accumulated Expenses rose 31.73% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 31.73%. This contributed to the annual value of $7.0 million for FY2024, which is 8.94% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Accumulated Expenses is $10.3 million, which was up 42.31% from $7.3 million recorded in Q2 2025.
  • Theravance Biopharma's Accumulated Expenses' 5-year high stood at $15.6 million during Q1 2021, with a 5-year trough of $4.5 million in Q1 2024.
  • In the last 3 years, Theravance Biopharma's Accumulated Expenses had a median value of $6.4 million in 2023 and averaged $6.5 million.
  • As far as peak fluctuations go, Theravance Biopharma's Accumulated Expenses tumbled by 71.66% in 2021, and later surged by 31.73% in 2025.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Accumulated Expenses stood at $12.8 million in 2021, then dropped by 19.40% to $10.3 million in 2022, then plummeted by 37.53% to $6.4 million in 2023, then rose by 8.94% to $7.0 million in 2024, then skyrocketed by 31.73% to $10.3 million in 2025.
  • Its Accumulated Expenses stands at $10.3 million for Q3 2025, versus $7.3 million for Q2 2025 and $5.4 million for Q1 2025.